Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285711 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2 study of Lupus Membranous Nephropathy, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 7
- Study locations
NCT03285711 is a Phase 2 study of Lupus Membranous Nephropathy that has completed, run by Gilead Sciences. The registered enrollment target is 9 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT03285711, a Phase 2 study of Lupus Membranous Nephropathy, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
Conditions Studied
Interventions
- DRUG Filgotinib
- DRUG Lanraplenib
- DRUG Lanraplenib placebo
- DRUG Filgotinib placebo
Study Locations (7)
Georgia
- Emory University School of Medicine - Atlanta
- Georgia Nephrology Research Institute - Lawrenceville
Alabama
- University of Alabama at Birmingham (UAB) - Birmingham
California
- Stanford University - Palo Alto
Florida
- University of Florida - Gainesville
Michigan
- University of Michigan - Ann Arbor
North Carolina
- University of North Carolina at Chapel Hill / UNC School of Medicine - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2020-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03285711
The ClinicalTrials.gov registry entry for NCT03285711 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Membranous Nephropathy appearing as the primary indexed condition, and to 4 interventions - of which Filgotinib is the first listed.
NCT03285711 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03285711 about?
NCT03285711 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)". The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
What is the current status of trial NCT03285711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-10-06. Estimated completion is 2020-02-03.
What conditions does trial NCT03285711 study?
This clinical trial studies the following conditions: Lupus Membranous Nephropathy.
What interventions are being tested in trial NCT03285711?
The interventions under investigation include: Filgotinib (DRUG), Lanraplenib (DRUG), Lanraplenib placebo (DRUG), Filgotinib placebo (DRUG).
Who is sponsoring clinical trial NCT03285711?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03285711 being conducted?
This trial has 7 study locations across Alabama, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.